Novartis acquired UK-based Ziarco Group, a dermatology biotech, for undisclosed financial terms. Lead asset ZPL-389, a once-daily oral H4 receptor antagonist in development for atopic dermatitis. Strategic addition to Novartis's dermatology pipeline alongside Cosentyx (anti-IL-17A).
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 5yr post-close.
Key facts
AnnouncedDec 16, 2016
ClosedDec 16, 2016
Deal value$420M
Deal typeAcquisition/Merger
Therapeutic areaAtopic dermatitis (eczema) and other dermatologic indications
IndicationsAtopic dermatitis (eczema) and other dermatologic indications